Comment: Worsening heart failure in the setting of dronedarone initiation

Annals of Pharmacotherapy

Volumn 45, Issue 5, 2011, Pages 690-

  Pantos, Constantinos ^a   Mourouzis, Iordanis ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; VANCOMYCIN; AMIODARONE; ANTIARRHYTHMIC AGENT; DRONEDARONE; DRUG DERIVATIVE;

ADULT; COHORT ANALYSIS; COMMUNITY HOSPITAL; CONSENSUS DEVELOPMENT; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LETTER; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; HEART FAILURE; MIDDLE AGED; MULTICENTER STUDY; NOTE; PATHOPHYSIOLOGY; TREATMENT FAILURE;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; TREATMENT FAILURE;

EID: 80052789325     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P075b     Document Type: Letter

References (16)

1. Coons JC, Plauger KM, Seybert AL, Sokos GG. Worsening heart failure in the setting of dronedarone initiation. Ann Pharmacother 2010;44: 1496-500. DOI 10.1345/aph.1P075
2. Køber L, Torp-Pedersen C, McMurray JJ, et al.; Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-87.
3. Jondeau G, Neuder Y, Eicher JC, et al.; B-CONVINCED Investigators. B-CONVINCED: Beta-blocker CONtinuation Vs INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J 2009;30:2186-92.
4. Pantos C, Mourouzis I, Cokkinos DV. New insights into the role of thyroid hormone in cardiac remodeling: time to reconsider? Heart Fail Rev 2011;16:79-96.
5. Iervasi G, Pingitore A, Landi P, et al. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation 2003; 107:708-13.
6. Pantos C, Dritsas A, Mourouzis I, et al. Thyroid hormone is a critical determinant of myocardial performance in patients with heart failure: potential therapeutic implications. Eur J Endocrinol 2007;157:515-20.
7. Galli E, Pingitore A, Iervasi G. The role of thyroid hormone in the pathophysiology of heart failure: clinical evidence. Heart Fail Rev 2010;15: 155-69.
8. Goldman S, McCarren M, Morkin E, et al. DITPA (3,5-Diiodothyropropionic Acid), a thyroid hormone analog to treat heart failure: phase II trial Veterans Affairs cooperative study. Circulation 2009;119:3093-100.
9. Pingitore A, Iervasi G, Gerdes MA. Letter by Pingitore et al. regarding article, ''DITPA (3,5-diiodothyropropionic acid), a thyroid hormone analog to treat heart failure: phase II trial Veterans Affairs cooperative study.'' Circulation 2010;121:e240.
10. Pantos C, Mourouzis I, Xinaris C, Papadopoulou-Daifoti Z, Cokkinos D. Thyroid hormone and ''cardiac metamorphosis'': potential therapeutic implications. Pharmacol Ther 2008;118:277-94.
11. Pantos C, Mourouzis I, Galanopoulos G, et al. Thyroid hormone receptor alpha1 downregulation in postischemic heart failure progression: the potential role of tissue hypothyroidism. Horm Metab Res 2010;42:718-24.
12. Han TS, Williams GR, Vanderpump MP. Benzofuran derivatives and the thyroid. Clin Endocrinol (Oxf) 2009;70:2-13.
13. Van Beeren HC, Jong WM, Kaptein E, Visser TJ, Bakker O, Wiersinga WM. Dronerarone acts as a selective inhibitor of 3,5,3¢-triiodothyronine binding to thyroid hormone receptor-alpha1: in vitro and in vivo evidence. Endocrinology 2003;144:552-8.
14. Pantos C, Mourouzis I, Malliopoulou V, et al. Dronedarone administration prevents body weight gain and increases tolerance of the heart to ischemic stress: a possible involvement of thyroid hormone receptor alpha1. Thyroid 2005;15:16-23.
15. Agelaki MG, Pantos C, Korantzopoulos P, et al. Comparative antiarrhythmic efficacy of amiodarone and dronedarone during acute myocardial infarction in rats. Eur J Pharmacol 2007;564:150-7.
16. Prescribing information. Dronedarone (Multaq). Bridgewater, NJ: Sanofi-Aventis US LLC, July 2009.